Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Second Natures peer-reviewed study published in JMIR Formative Research (2025) compared both medications within our programme: 3 Tirzepatide (Mounjaro) cohort (209 people): 22.1% average weight loss at 12 months 95.2% achieved at least 10% weight loss 83.7% achieved at least 15% weight loss Semaglutide (Wegovy) cohort (130 people): 17.1% average weight loss at 12 months 83.1% achieved at least 10% weight loss 56.2% achieved at least 15% weight loss Both cohorts exceeded clinical trial results, suggesting that comprehensive behavioural support enhances outcomes regardless of which medication you use
Get this number wrong and every other refinement in your model is irrelevant
I don't want no donut
Yeast 14 , 115132 (1998)
Key Benefits Weight Loss Reduced inflammatory biomarkers Enhanced insulin synthesis Blood sugar regulation Controlled food cravings Slow digestion to maintain satiety Significant improvement in cardiovascular risk factors associated with obesity Concerns treated Weight Insulin Resistance Appetite Blood Sugar Cardiovascular Health High Cholesterol What to Expect Always free consultations InBody Analysis Throughout Continuous support Weekly, bi-weekly, or monthly follow ups Education Diet and lifestyle coaching Symptom management Monthly Lipotropic Injections HOW DOES TIRZEPATIDE WORK
US$ 29.40
US$ 26.46
US$ 23.20
US$ 26.52
US$ 25.54
US$ 23.60
US$ 28.64
